Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention

Giampaolo Niccoli, Simona Giubilato, Eleonora Russo, Cristina Spaziani, Andrea Leo, Italo Porto, Antonio M. Leone, Francesco Burzotta, Silvia Riondino, Fabio Pulcinelli, Luigi M. Biasucci, Filippo Crea

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results: A total of 47 consecutive patients (age, 62.5 ± 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of ≤2 or final TIMI flow of 3 with a myocardial blush grade of

Original languageEnglish
Pages (from-to)1843-1850
Number of pages8
JournalEuropean Heart Journal
Volume29
Issue number15
DOIs
Publication statusPublished - Aug 2008

Keywords

  • Acute myocardial infarction
  • No-reflow
  • Platelets
  • Primary percutaneous coronary intervention
  • Thromboxane A2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention'. Together they form a unique fingerprint.

Cite this